IN2014DN10653A - - Google Patents
Info
- Publication number
- IN2014DN10653A IN2014DN10653A IN10653DEN2014A IN2014DN10653A IN 2014DN10653 A IN2014DN10653 A IN 2014DN10653A IN 10653DEN2014 A IN10653DEN2014 A IN 10653DEN2014A IN 2014DN10653 A IN2014DN10653 A IN 2014DN10653A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- diagnoses
- useful
- detecting
- treatment
- Prior art date
Links
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 abstract 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 abstract 2
- 241001529936 Murinae Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649110P | 2012-05-18 | 2012-05-18 | |
| US13/804,227 US20130309223A1 (en) | 2012-05-18 | 2013-03-14 | CD33 Antibodies And Use Of Same To Treat Cancer |
| PCT/US2013/041209 WO2013173496A2 (en) | 2012-05-18 | 2013-05-15 | Cd33 antibodies and use of same to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10653A true IN2014DN10653A (cg-RX-API-DMAC7.html) | 2015-09-11 |
Family
ID=49581477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10653DEN2014 IN2014DN10653A (cg-RX-API-DMAC7.html) | 2012-05-18 | 2013-05-15 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20130309223A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2850104B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6454269B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102100467B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104936617B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2013262788B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2873286C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2850104T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA029987B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2686618T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL235733B (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN10653A (cg-RX-API-DMAC7.html) |
| MX (1) | MX350808B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ702748A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201407610WA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI593707B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013173496A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201409224B (cg-RX-API-DMAC7.html) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CA3187392A1 (en) | 2013-10-15 | 2015-04-23 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| EA034123B1 (ru) * | 2013-11-25 | 2019-12-30 | Сиэтл Дженетикс, Инк. | Получение антител для конъюгации из культур клеток cho |
| SG11201604784XA (en) * | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
| WO2015123265A1 (en) | 2014-02-11 | 2015-08-20 | Seattle Genetics, Inc. | Selective reduction of proteins |
| KR20160120777A (ko) | 2014-02-17 | 2016-10-18 | 시애틀 지네틱스, 인크. | 친수성 항체-약물 컨쥬게이트 |
| EP3126390B2 (en) | 2014-04-03 | 2026-01-07 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| US9777061B2 (en) * | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| US20180002427A1 (en) | 2015-01-26 | 2018-01-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| JP7376977B2 (ja) | 2015-06-12 | 2023-11-09 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| FI3316909T3 (fi) * | 2015-06-30 | 2023-09-07 | Seagen Inc | NTB-A-vasta-aineita ja liittyviä koostumuksia ja menetelmiä |
| CA3006000A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| JP7073266B2 (ja) | 2016-03-25 | 2022-05-23 | シージェン インコーポレイテッド | Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス |
| EP3442591A4 (en) * | 2016-04-15 | 2019-11-20 | Seattle Genetics, Inc. | COMBINATIONS OF CD33 ANTIBODY-ACTIVE CONJUGATES WITH HYPOMETHYLATING AGENTS |
| EP3463463A4 (en) | 2016-06-03 | 2020-01-15 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| US11191771B2 (en) | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
| WO2018031690A1 (en) | 2016-08-09 | 2018-02-15 | Seattle Genetics, Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
| EA201990890A1 (ru) | 2016-10-18 | 2019-10-31 | Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида | |
| JP7105235B2 (ja) | 2016-12-01 | 2022-07-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔイメージングのための放射性標識された抗ｐｄ－ｌ１抗体 |
| MX2019006374A (es) | 2016-12-02 | 2019-09-11 | Univ Southern California | Receptores inmunes sinteticos y metodos de usos de ellos. |
| CN110352074B (zh) | 2017-02-28 | 2024-07-16 | 思进股份有限公司 | 用于偶联的半胱氨酸突变抗体 |
| CN110662554A (zh) | 2017-02-28 | 2020-01-07 | Vor生物制药股份有限公司 | 用于抑制谱系特异性蛋白质的组合物和方法 |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| MA49152A (fr) * | 2017-05-17 | 2020-03-25 | Immunogen Inc | Schémas posologiques d'immunoconjugués anti-cd33 |
| WO2018218207A1 (en) * | 2017-05-26 | 2018-11-29 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| TWI811229B (zh) | 2017-08-03 | 2023-08-11 | 美商阿列克特有限責任公司 | 抗trem2抗體及其使用方法 |
| PE20200486A1 (es) * | 2017-08-03 | 2020-03-03 | Alector Llc | Anticuerpos anti-cd33 y metodos para utilizarlos |
| IL273471B2 (en) | 2017-09-29 | 2023-09-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a pyrrolobenzodiazepine derivative |
| CN111989339A (zh) | 2018-02-20 | 2020-11-24 | 西雅图基因公司 | 疏水性奥瑞他汀f化合物及其缀合物 |
| KR20200133222A (ko) * | 2018-02-20 | 2020-11-26 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33을 표적으로 하는 항체 가변 도메인, 및 이의 용도 |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| AU2019333104A1 (en) | 2018-08-28 | 2021-03-25 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US12247073B2 (en) * | 2018-08-31 | 2025-03-11 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| WO2020056170A1 (en) * | 2018-09-12 | 2020-03-19 | Fred Hutchinson Cancer Research Center | Reducing cd33 expression to selectively protect therapeutic cells |
| JP2022501319A (ja) * | 2018-09-25 | 2022-01-06 | アカデミア シニカAcademia Sinica | 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用 |
| JP7553440B2 (ja) | 2018-11-07 | 2024-09-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 抗ｃｄ３３免疫細胞癌療法 |
| TW202031298A (zh) | 2018-11-14 | 2020-09-01 | 日商第一三共股份有限公司 | 抗ｃｄｈ６抗體－吡咯并苯二氮呯衍生物結合物 |
| CN120329441A (zh) * | 2019-02-22 | 2025-07-18 | 纪念斯隆凯特琳癌症中心 | Cd33抗体和使用所述抗体治疗癌症的方法 |
| TWI856078B (zh) | 2019-03-25 | 2024-09-21 | 日商第一三共股份有限公司 | 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途 |
| WO2020196475A1 (ja) | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート |
| TWI841715B (zh) | 2019-03-27 | 2024-05-11 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途 |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| AU2020287378A1 (en) * | 2019-06-06 | 2022-02-03 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| WO2021202770A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Human anti-cd33 antibodies and uses thereof |
| CN115297932A (zh) * | 2020-03-31 | 2022-11-04 | 弗莱德哈钦森癌症中心 | 抗cd33抗体和其用途 |
| JP2023520930A (ja) | 2020-04-10 | 2023-05-22 | シージェン インコーポレイテッド | 電荷多様性リンカー |
| US20210402001A1 (en) * | 2020-06-30 | 2021-12-30 | David I. Cohen | Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers |
| CA3191395A1 (en) | 2020-09-02 | 2022-03-10 | Daiichi Sankyo Company, Limited | Novel endo-.beta.-n-acetylglucosaminidase |
| JP2023552919A (ja) * | 2020-11-11 | 2023-12-19 | ベルサピューティクス インコーポレイテッド | Ｗｎｔ受容体ｒｙｋに対する抗体バリアント |
| MX2023008261A (es) | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
| US20240115607A1 (en) | 2021-01-26 | 2024-04-11 | Cytocares (Shanghai) Inc. | Chimeric antigen receptor (car) constructs and nk cells expressing car constructs |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| KR20230171980A (ko) | 2021-04-20 | 2023-12-21 | 씨젠 인크. | 항체 의존성 세포 독성의 조절 |
| CA3221398A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
| WO2023100829A1 (ja) | 2021-11-30 | 2023-06-08 | 第一三共株式会社 | プロテアーゼ分解性マスク抗体 |
| WO2023153442A1 (ja) | 2022-02-09 | 2023-08-17 | 第一三共株式会社 | 環境応答性マスク抗体及びその利用 |
| TW202346322A (zh) | 2022-03-02 | 2023-12-01 | 日商第一三共股份有限公司 | 含Ｆｃ分子之製造方法 |
| PE20242179A1 (es) | 2022-03-17 | 2024-11-07 | Seagen Inc | Conjugados de camptotecina |
| EP4634227A1 (en) | 2022-12-13 | 2025-10-22 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| CN116375874B (zh) * | 2023-04-14 | 2023-12-26 | 上海精翰生物科技有限公司 | 一种cd33抗体及其应用 |
| WO2025090774A1 (en) | 2023-10-24 | 2025-05-01 | Seagen Inc. | Chemotherapeutic compounds and methods of use |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025174974A1 (en) * | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anti-cd33 antibodies and uses thereof |
| CN119080935A (zh) * | 2024-10-11 | 2024-12-06 | 上海市同仁医院 | 一种抗人SMIM45-107aa单克隆抗体及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| CN100489892C (zh) | 1999-02-05 | 2009-05-20 | 三星电子株式会社 | 恢复描述图像的纹理特征的图像纹理描述符的方法及装置 |
| US6759045B2 (en) * | 2000-08-08 | 2004-07-06 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| PT1578446E (pt) * | 2002-11-07 | 2015-07-22 | Immunogen Inc | Anticorpos anti-cd33 e processo para tratamento de leucemia mieloide aguda usando os mesmos |
| WO2004078215A2 (en) | 2003-02-28 | 2004-09-16 | The Board Of Trustees Of The University Of Illinois | Use of antibody conjugated deoxycytidine kinase for adept |
| KR101438983B1 (ko) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| EP2298807A3 (en) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| CN104447992A (zh) | 2004-09-23 | 2015-03-25 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| EP1917020B1 (en) | 2005-07-07 | 2016-05-25 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
| WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| LT2211904T (lt) | 2007-10-19 | 2016-11-25 | Seattle Genetics, Inc. | Cd19 surišantys agentai ir jų panaudojimas |
| US9416192B2 (en) | 2008-08-05 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| JP5995442B2 (ja) * | 2009-03-10 | 2016-09-21 | 株式会社ジーンテクノサイエンス | ヒト化ｋ３３ｎモノクローナル抗体の作製、発現及び解析 |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| BR112012026801B8 (pt) | 2010-04-15 | 2021-05-25 | Medimmune Ltd | conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CA2884313C (en) * | 2012-12-13 | 2023-01-03 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| CA2901575C (en) * | 2013-03-13 | 2022-08-30 | Seattle Genetics, Inc. | Cyclodextrin and antibody-drug conjugate formulations |
-
2013
- 2013-03-14 US US13/804,227 patent/US20130309223A1/en not_active Abandoned
- 2013-05-15 AU AU2013262788A patent/AU2013262788B2/en not_active Ceased
- 2013-05-15 JP JP2015512801A patent/JP6454269B2/ja not_active Expired - Fee Related
- 2013-05-15 IN IN10653DEN2014 patent/IN2014DN10653A/en unknown
- 2013-05-15 KR KR1020147035516A patent/KR102100467B1/ko active Active
- 2013-05-15 MX MX2014013866A patent/MX350808B/es active IP Right Grant
- 2013-05-15 US US14/401,837 patent/US9587019B2/en active Active
- 2013-05-15 WO PCT/US2013/041209 patent/WO2013173496A2/en not_active Ceased
- 2013-05-15 CN CN201380026079.9A patent/CN104936617B/zh active Active
- 2013-05-15 EP EP13790467.8A patent/EP2850104B1/en active Active
- 2013-05-15 EA EA201492137A patent/EA029987B1/ru unknown
- 2013-05-15 EP EP18171884.2A patent/EP3421048A1/en not_active Withdrawn
- 2013-05-15 SG SG11201407610WA patent/SG11201407610WA/en unknown
- 2013-05-15 NZ NZ702748A patent/NZ702748A/en not_active IP Right Cessation
- 2013-05-15 DK DK13790467.8T patent/DK2850104T3/en active
- 2013-05-15 CA CA2873286A patent/CA2873286C/en active Active
- 2013-05-15 KR KR1020207010113A patent/KR102241478B1/ko active Active
- 2013-05-15 ES ES13790467.8T patent/ES2686618T3/es active Active
- 2013-05-17 TW TW102117539A patent/TWI593707B/zh active
-
2014
- 2014-11-17 IL IL235733A patent/IL235733B/en unknown
- 2014-12-15 ZA ZA2014/09224A patent/ZA201409224B/en unknown
-
2017
- 2017-01-20 US US15/411,947 patent/US10787514B2/en active Active
-
2018
- 2018-05-17 AU AU2018203508A patent/AU2018203508C1/en not_active Ceased
-
2020
- 2020-05-22 AU AU2020203365A patent/AU2020203365B2/en not_active Ceased
- 2020-07-29 US US16/942,647 patent/US20210047404A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10653A (cg-RX-API-DMAC7.html) | ||
| IL311371A (en) | CD3 antibodies of human origin or chimeras | |
| MX2014009751A (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
| GEP20217331B (en) | Anti-tigit antibodies | |
| MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
| PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
| PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
| IL241261B (en) | Cancer treatment using human receptor chimeric anti-cd19 antigen | |
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
| PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| PH12014500841B1 (en) | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE | |
| MX2014014376A (es) | Anticuerpos de anti-biotina y metodos de uso. | |
| MX353951B (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
| PL2984108T3 (pl) | Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu | |
| MX362497B (es) | Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo. | |
| EP2812694A4 (en) | TESTS AND METHODS FOR DIAGNOSING OVARIAN CANCER | |
| EP2852411A4 (en) | ANTI-CCL2 ANTIBODIES FOR THE TREATMENT OF SCLEROMERMIA |